SEC Form 4 · accession 0001364846-26-000003
ImmunityBio, Inc. · IBRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Bruce Wendel
Director
Period of report
Jun 9, 2026
Accepted (ET)
Jun 10, 2026 · 8:11 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001326110
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $7.25 | Jun 9, 2026 | A | 65,600 | A | — | Jun 9, 2036 | Common Stock | 65,600 | 65,600 | D |
Explanation of responses
- F1Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's 2025 Equity Incentive Plan) through such applicable vesting date, one hundred percent (100%) of the shares subject to the award will vest on the earlier to occur of June 9, 2027 or the date immediately preceding the next annual meeting of stockholders.